AstraZeneca Boosts Structure-Activity R&D With Conformetrix's New NMR-Based Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
With an approach to determining three-dimensional drug structures said to be as accurate as crystallography but takes only weeks rather than months, the U.K.'s Conformetrix snags AstraZeneca for its first research collaboration.